Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study

BMC Infectious Diseases

Table 8 Factors associated with the safety of DTG-based ART (N = 461)

Variable	Side Effects Experienced		Crude Odds Ratio (95% CI)
Variable	Yes	No	Crude Odds Ratio (95% CI)
Age Group
18 − 30 31 − 50 > 50	19 150 90	14 118 70	1 1.000 (0.390, 2.563) 1.004 (0.372, 2.708
Gender
Male Female	141 118	86 116	1 1.747 (1.089, 2.803)
ART Usage
ART experienced ART naïve	246 13	185 17	1 -
CD4 count (cells/mm³)
< 200 200 − 350 351 − 500 > 500	10 28 51 134	17 18 39 105	1 0.260 (0.063, 1.076) 0.305 (0.081, 1.148) 0.287 (0.078, 1.058)
VL (copies/ml)
< 50 50 − 999 ≥ 10,000	226 14 4	170 14 2	1 1.557 (0.635, 3.814) 0.403 (0.035, 4.591)
Clinical Staging
1 2 3	210 39 6	172 25 1	1 0.586 (0.313, 1.097) 0.000
Co-morbidity
Hypertension Diabetes Hypercholesterolemia Arthritis Tuberculosis	66 20 16 17 5	48 8 10 13 3	1.174 (0.694, 1.976) 1.582 (0.632, 3.961) 0.730 (0.285, 1.869) 1.343 (0.589, 3.060) 0.799 (0.126, 5.073)

ISSN: 1471-2334